EGRX (Eagle Pharmaceuticals) 3-1 Month Momentum %: -29.52% (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EGRX Eagle Pharmaceuticals Inc EGRX
16 GF Score
Price $0.75
View Full Analysis

What is Eagle Pharmaceuticals 3-1 Month Momentum %?

Eagle Pharmaceuticals EGRX 16 3-1 Month Momentum % is -29.52% as of Sep. 07, 2026. GuruFocus rates EGRX with a GF Score™ of 16/100.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-07), Eagle Pharmaceuticals's 3-1 Month Momentum % is -29.52%.

The industry rank for Eagle Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:

EGRX's 3-1 Month Momentum % is not ranked
in the Drug Manufacturers industry.
Industry Median: -0.135 vs EGRX: -29.52

Eagle Pharmaceuticals  (OTCPK:EGRX) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Eagle Pharmaceuticals 3-1 Month Momentum % Related Terms

EGRX vs IXHL, RMTI, CHHE: 3-1 Month Momentum % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eagle Pharmaceuticals 3-1 Month Momentum % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Eagle Pharmaceuticals's 3-1 Month Momentum % falls into.


EGRX
16GF Score
Eagle Pharmaceuticals Inc EGRX
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eagle Pharmaceuticals  (OTCPK:EGRX) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -29.52% mean?
Eagle Pharmaceuticals (EGRX) has a 3-1 Month Momentum % of -29.52% as of Sep. 07, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Eagle Pharmaceuticals and its competitors.
Is Eagle Pharmaceuticals' 3-1 Month Momentum % too high?
Eagle Pharmaceuticals' current 3-1 Month Momentum % is -29.52%. Overall, Eagle Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Eagle Pharmaceuticals' 3-1 Month Momentum % compare to IXHL and RMTI?
Eagle Pharmaceuticals' 3-1 Month Momentum % of -29.52% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Eagle Pharmaceuticals and its competitors. Eagle Pharmaceuticals's current 3-1 Month Momentum % is -29.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eagle Pharmaceuticals stock overvalued right now?
Eagle Pharmaceuticals (EGRX) has a current 3-1 Month Momentum % of -29.52%. The current 3-1 Month Momentum % is -29.52%. Eagle Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Eagle Pharmaceuticals (EGRX), the current 3-1 Month Momentum % is -29.52% as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eagle Pharmaceuticals Business Description

Address 50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advance stages of development and is under review for approval by the Food and Drug Administration.
16GF Score

Get the complete analysis for EGRX

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price